Crucial US Advisory Committee to Vote on Modifying Newborn Hepatitis B Vaccine Guideline
Following a hold-up and a particularly heated session, a government vaccine expert group was set to cast ballots on Friday regarding a potential change to the longstanding recommendation that each baby be vaccinated against hepatitis B.
Intense Discussion and a Delayed Ballot
The initial day of the meeting on Thursday was marked by heated debate over limiting availability to the hepatitis B vaccine for newborns and a decision to postpone the decision by a day to give members more time to review the wording. The committee, which guides the Centers for Disease Control and Prevention on immunization practices, had twice before postponed.
“Is there any definitive data of damage of giving this vaccination before 30 days? Or is this speculation?” questioned one adviser.
In response, another participant stated, “There is scant proof about the enduring danger.”
Present Protocol and Possible Consequences
The vaccine is presently advised for all infants within 24 hours of delivery to stop transmission of hepatitis B, which can lead to significant hepatic injury. It has been provided to over a billion individuals for over thirty years.
The Georgia assembly presented no recent proof of damage attributable to the vaccine. Specialists note any change to the present hepatitis B vaccine regimen could have significant and far-reaching repercussions for childhood health in the United States.
Panel Composition and Recent Changes
The consultative group can only offer guidance to the leader of the CDC. The panel's membership has undergone changes this week, with the statement that the committee’s most recent chair would leave for an official role and be substituted with a cardiologist who has been critical of other vaccines.
The board includes multiple vaccination critics who are in agreement with a aim to revamp – and perhaps, in some cases, eliminate – long-established vaccination recommendations.
